<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00125372</url>
  </required_header>
  <id_info>
    <org_study_id>D-0453</org_study_id>
    <nct_id>NCT00125372</nct_id>
  </id_info>
  <brief_title>Study of Tarceva and Targretin in Stage I-II Lung Cancer</brief_title>
  <official_title>A Clinical and Pharmacologic Study of the Combination of Erlotinib and Bexarotene in Resectable Clinical Stage I-II Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ligand Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn the effects on lung cancer of 2 new drugs, Tarceva and
      Targretin, given in combination before surgical removal of the tumor. Tarceva is approved by
      the Food and Drug Administration (FDA) for lung cancer. Targretin is approved for the
      treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Erlotinib 150mg and bexarotene 400mg/m2 will be administered orally for 7-9 days prior to
      thoracotomy. Plasma samples will be collected on the day before surgery and along with tissue
      samples on the day of the thoracotomy. Analyses will be done on the resected specimen and it
      will be compared to the pre-study diagnostic specimen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pre and post study analysis of cyclin D1, epidermal growth factor receptor (EGFR), phospho-EGFR, and Ki-67</measure>
    <time_frame>Analyses to be performed after accrual goal has been met</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tumor tissue concentrations of erlotinib and bexarotene and correlation with plasma levels</measure>
    <time_frame>Analyses to be performed after accrual goal has been met</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mutational analysis of EGFR and its correlation with response</measure>
    <time_frame>Analyses to be performed after accrual goal has been met</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Carcinoma, Non-small-cell Lung</condition>
  <arm_group>
    <arm_group_label>Erlotinib and Bexarotene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib (Tarceva) and bexarotene (Targretin)</intervention_name>
    <description>Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy</description>
    <arm_group_label>Erlotinib and Bexarotene</arm_group_label>
    <other_name>Tarceva</other_name>
    <other_name>Targretin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Resectable stage I or II non-small-cell lung cancer

          -  Prior tissue biopsy (not cytology) available for research analysis

          -  Adequate hepatic and renal function

        Exclusion Criteria:

          -  Prior chemotherapy or radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konstantin H Dragnev, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norris Cotton Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2005</study_first_submitted>
  <study_first_submitted_qc>July 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2005</study_first_posted>
  <last_update_submitted>July 14, 2014</last_update_submitted>
  <last_update_submitted_qc>July 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tarceva</keyword>
  <keyword>targretin</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>carcinoma, non-small cell lung cancer</keyword>
  <keyword>nsclc</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bexarotene</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

